ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

586
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
02 May 2023 10:56

Hong Kong Connect Flows Monthly: China Mobile, SMIC, PetroChina, Sensetime, CNOOC, CCB, Tencent

We analyzed the Hong Kong Connect Scheme for April and highlight flows for China Mobile, SMIC, PetroChina, Sensetime, CNOOC, CCB, Tencent, HKEx.

Logo
353 Views
Share
01 May 2023 10:00

HK Short Interest Weekly: Galaxy Ent, Baba, East Buy, Anta Sports, Zijin Mining, Li Auto

We analyzed the latest HK SFC report for aggregate short position as of Apr 21st and highlight short interest changes in Galaxy Ent, Baba, East...

Logo
375 Views
Share
23 Apr 2023 10:00

HK Short Interest Weekly: Li Auto, Wuxi Bio, Baba, Tencent, Sensetime

We analyzed the latest HK SFC report for aggregate short position as of Apr 14th and highlight short interest changes in Li Auto, Wuxi Bio, Baba,...

Logo
416 Views
Share
13 Apr 2023 08:55

A Different View on Global CDMO - The Industry Trend, the Major Players, and the Outlook

After the release of 2022 annual reports by leading global CDMOs (Lonza, WuXi Bio, Samsung Biologics), we shared our different views and identified...

Logo
461 Views
Share
03 Apr 2023 10:50

Hong Kong Connect Flows Monthly: 1Y High Inflows in March

We analyzed the Hong Kong Connect Scheme for March and highlight flows for Tencent, Meituan, China Mobile, ICBC, Bilibili, CCB, Geely, Sunny Optical.

Logo
508 Views
Share
x